EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

Alnylam Pharmaceuticals, Inc. (ALNY) had EBITDA of $-2.25M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$773.69M
Net Income	$-66.28M
Cost of Goods Sold	$142.95M
Gross Profit	$630.74M
Operating Expenses	$789.89M
Operating Income	$-16.20M
Non-Operating Income/Expense	$-19.16M
Pre-Tax Income	$-35.36M
Normalized Pre-Tax Income	$-35.36M
Income after Taxes	$-66.28M
Income from Continuous Operations	$-66.28M
Consolidated Net Income/Loss	$-66.28M
Normalized Income after Taxes	$-66.28M
EBIT	$-16.20M
EBITDA	$-2.25M
Weighted-Average Shares Outstanding (Basic)	130.63M
Weighted-Average Shares Outstanding (Diluted)	130.63M
Earnings per Share (EPS) (Basic)	$-0.51
Earnings per Share (EPS) (Diluted)	$-0.51
Balance Sheet Financials
Current Assets	$3.64B
Property, Plant, and Equipment	$499.79M
Long-Term Assets	$922.32M
Total Assets	$4.57B
Current Liabilities	$1.30B
Long-Term Debt	$1.03B
Long-Term Liabilities	$3.01B
Total Liabilities	$4.32B
Common Equity	$250.59M
Tangible Shareholders Equity	$250.59M
Shareholders Equity	$250.59M
Common Shares Outstanding	130.98M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$35.42M
Cash Flow from Investing Activities	$-27.61M
Cash Flow from Financial Activities	$97.84M
Beginning Cash	$968.65M
End Cash	$1.12B
Increase/Decrease in Cash	$147.21M
Stock-Based Compensation	$168.39M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.80
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.80
Debt to Equity Ratio	4.10
Gross Margin	81.52%
Operating Margin	-2.09%
EBIT Margin	-2.09%
EBITDA Margin	--
Pre-Tax Profit Margin	-4.57%
Profit Margin	-8.57%
Free Cash Flow	$12.15M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.17
Inventory Turnover	1.99
Receiveable Turnover	1.36
Days Sales in Receivables	65.97
Return on Equity	-26.45%
Return on Tangible Equity	-26.45%
Return on Assets	-1.45%
Return on Investments	-5.19%
Book Value Per Share	$1.91
Free Cash Flow per Share	$0.09
Operating Cash Flow per Share	$0.27

Data from Zacks Investment Research, Inc.